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Objectives This study evaluated the use of a paclitaxel-eluting balloon (PEB) for treatment of femo-
ropopliteal arterial disease.
Background Conventional balloon angioplasty and stenting in this setting is associated with high
restenosis rates within 12 months. Recent data suggest that PEB use may reduce restenosis. Twelve-
month outcomes following PEB use with provisional stenting are described.
Methods This prospective registry enrolled patients (Rutherford class 2 to 4) with reference vessel
diameter of 3 to 7 mm and lesion/occlusion length 15 cm. Endpoints included primary patency
rate, target lesion revascularization, and changes in Rutherford class and ankle-brachial index. Walk-
ing capacity, absolute claudication distance, and quality of life were also assessed.
Results The registry enrolled 105 patients. Baseline ankle-brachial index was 0.56  0.15. Baseline
Rutherford classiﬁcation was class 2 or 3 for most patients (91.5%). Most lesions were located in the
superﬁcial femoral artery (77.1%). Mean lesion length was 76.3  38.3 mm; 29.8% of lesions were
total occlusions. The device was successfully used in all patients and only 12.3% of lesions required
stenting. At 12-month follow-up, 92 of 105 patients (87.6%) were evaluable; the primary patency
rate was 83.7%; the target lesion revascularization rate was 7.6%; 85.6% of patients were Rutherford
class 0 or 1; and mean ankle-brachial index was 0.86  0.15. Quality of life and absolute claudica-
tion distance showed signiﬁcant improvement from baseline to 12-month follow-up.
Conclusions PEB treatment of femoropopliteal arterial disease resulted in consistent clinical
improvement across multiple endpoints with a low rate of stenting and target lesion
revascularization. (J Am Coll Cardiol Intv 2012;5:331–8) © 2012 by the American College of
Cardiology Foundation
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332Treatment of femoropopliteal artery disease by percutane-
ous transluminal angioplasty (PTA) is limited by high rates
of restenosis (40% to 60%) 6 to 12 months after conven-
tional balloon angioplasty (1–4). Alternative therapies, such
as brachytherapy, atherectomy, and cryoplasty, have not
been shown to be superior to PTA in clinical trials (5–7).
Randomized controlled trials comparing nitinol stents with
PTA to treat moderate to long superficial femoral artery
(SFA) lesions demonstrated a significant reduction in reste-
nosis with stenting (4,8); however, no significant difference
between nitinol stenting and PTA was demonstrated in
short SFA lesions (mean length: 4.5 cm) (9). The successful
See page 339
reduction of restenosis seen with drug-eluting stent treat-
ment of coronary artery disease was not observed in several
studies of drug-eluting stent use for obstructive SFA disease
(10,11). Although, a recent clini-
cal trial demonstrated a significant
improvement in primary patency
at 1 and 2 years with a polymer-
free paclitaxel-eluting stent versus
PTA (12).
The high mechanical stress
(bending, compression, torsion)
that occurs with normal patient
movement in the femoropopli-
teal arteries is associated with an
increased risk for stent fractures
and abnormal tortuosities in the
adjacent nonstented vessel seg-
ments and the deformations of
those segments are amplified
due to the presence of stents
(3,13–17). Stents may also con-
stitute a potential barrier for subsequent surgical or endo-
vascular treatment. Hence, an alternative therapy that may
similarly reduce restenosis and improve clinical outcome
with minimal need for stent implantation (i.e., mainly
reserved for sealing flow-limiting dissections) has been
explored.
The potential advantages of an efficacious stent-free
approach and promising pre-clinical research led to consid-
eration of drug-eluting balloon technology for prevention of
restenosis in this complex peripheral artery disease popula-
tion (13,18–20).
Paclitaxel is a potent antineoplastic drug that, in small
concentrations, delivered locally provides sustained inhibi-
tion of vascular smooth muscle cell proliferation and migra-
tion (18). Pre-clinical studies of paclitaxel-coated balloons
in a porcine model of peripheral vascular disease showed
Abbreviations
and Acronyms
ABI  ankle-brachial index
ACD  absolute claudication
distance
PEB  paclitaxel-eluting
balloon(s)
PSVR  peak systolic
velocity ratio
PTA  percutaneous
transluminal angioplasty
QOL  quality of life
SFA  superficial femoral
artery
TLR  target lesion
revascularizationthat neointimal proliferation was significantly inhibited wwithout evidence of adverse effects (19,20). Subsequently,
randomized trials comparing paclitaxel-eluting balloons
(PEB) with conventional uncoated balloon angioplasty in
patients with SFA disease were undertaken and demon-
strated significant reduction in restenosis rates 6 months
after intervention (21–23).
The In.Pact Admiral PEB (Medtronic Inc., Frauenfeld,
Switzerland) uses a proprietary hydrophilic coating formu-
lation (Freepac) to facilitate the delivery of paclitaxel from
the balloon surface during dilation. The current trial is an
observational registry designed to prospectively evaluate the
safety and effectiveness of the In.Pact Admiral PEB when
used in routine practice with a strict provisional stenting
strategy, for treatment of patients with symptoms of clau-
dication and rest pain due to femoropopliteal ischemic
vascular disease. Primary patency and reintervention rates at
6 and 12 months, as well as changes in functional status and
health-related quality of life (QOL) are reported.
Methods
Study design and patient population. The safety and efficacy
f PEB technology for treatment of femoropopliteal isch-
mic vascular disease was prospectively evaluated in this
linical registry. The registry enrolled consecutive pa-
ients who met eligibility requirement from 6 participat-
ng centers throughout Italy. The registry was approved
y local ethics committees, and all enrolled patients were
equired to sign informed consent forms before treat-
ent. Patients were treated in accordance with the standard
ractices of the institution providing care and using the
n.Pact Admiral PEB currently on the market. Technical
etails regarding this PEB have been previously described (24).
Adult patients diagnosed with peripheral artery disease
or claudication or rest pain as per Rutherford classes 2
hrough 4 were considered for enrollment. Angiographic
nclusion criteria included the SFA and first 2 segments of
he proximal popliteal target vessel with reference diameter
etween 3 and 7 mm and lesion and/or occlusion length
15 cm. Long diffuse stenoses and occlusions or multiple
djacent lesions or occlusions were cumulatively considered
nd treated as a single lesion. Patients were required to have
dequate runoff with evidence of at least 1 patent crural
essel to the foot either pre-existing or re-established
patients were eligible if an impaired outflow vessel [50%
tenosis] was successfully treated). Good inflow in the
ortic-iliac and common femoral districts (either pre-
xisting or re-established) was also required for patient
nclusion. Long (15 cm) stenosis (50%) or occlusions in
his area constituted an exclusion criterion, whereas patients
resenting with shorter (15 cm) stenosis (50%) and
cclusions were eligible if these inflow lesions could be
uccessfully treated before the target SFA lesion. Patients
ith a previously implanted stent in the target lesion,
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333aneurysm in the target vessel, or acute thrombus in the
target limb were excluded. Other exclusions include failure
to cross the target lesion with a guidewire, and use of
alternative therapies, such as atherectomy, cutting balloon,
or laser or radiation therapy as part of the index procedure.
Procedure. Details of the PTA procedure using the drug-
luting balloon have been previously described (18). In brief,
atients not taking aspirin and clopidogrel before study
nrollment received loading doses of 300 mg of aspirin and
00 mg of clopidogrel 12 h before the procedure. Post-
rocedure patients were prescribed 100 mg/day of aspirin to
e taken indefinitely and 75 mg clopidogrel daily for 12
eeks and in patients requiring a stent for 6 months.
atients received a bolus of 5,000 IU of heparin after
nsertion of the sheath in the common femoral artery.
ascular access was accomplished via the contralateral
pproach in most patients. After crossing the lesion with a
uidewire, pre-dilation (2 min) with an undersized, shorter
ncoated balloon (0.5 to 1 mm smaller) was followed by
nsertion of the appropriate size and length PEB. The target
esion was dilated 10 mm beyond both ends of the lesion
sing a PEB vessel/balloon ratio of 1:1 (based on visual
stimation) and an inflation time of 3 min at 6 to 12 atm.
tudy balloons were inflated only once. An additional long
nflation with a shorter (to avoid geographic miss) uncoated
alloon was performed if angiography revealed persistent
tenosis 50% or a flow-limiting dissection. If suboptimal
esults persisted (stenosis 50% or flow-limiting dissec-
ion), self-expanding nitinol stents were implanted.
Endpoints. The primary endpoint at 12 months after inter-
ention was the primary patency rate defined as freedom
rom the combined endpoints of target lesion revasculariza-
ion (TLR), occlusion, and 50% restenosis in the treated
esion. Duplex ultrasonography was performed to assess
estenosis and 50% restenosis was defined by a peak
ystolic velocity ratio (PSVR) 2.4. Rates of TLR, death,
nd amputation were also analyzed. Secondary endpoints
ere change in Rutherford class and ankle-brachial index
ABI) from baseline to 12 months. Walking capacity and
bsolute claudication distance (ACD) were evaluated as
unctional capacity measures. Walking capacity was mea-
ured using a validated 5-point walking impairment ques-
ionnaire that assessed walking distance, speed, ability to
limb stairs, and symptoms with walking (25). ACD was
efined as the distance at which the patient could no longer
mbulate based on the 6-min walking test. All endpoints
ere assessed at baseline and at 3, 6, and 12 months after
he procedure. The impact of treatment on health-related
OL was assessed using the Euro QoL-5D Question-
aire at the same time points (26). This tool looks at 5
imensions of health: mobility, self-care, usual activities,
ain/discomfort, and anxiety/depression. Each dimen-
ion has 3 levels: no problems, some problems, or extreme
roblems. During follow-up visits, each patient com-leted a visual analogue scale (0 to 100) to assess their
verall health state. Adverse events, including thrombosis
n the target vessel, were collected throughout the study
eriod.
Post-procedural angiography was done to determine per-
entage of residual stenosis; total treated lesion length; and
evice, technical, and procedural success rates. Device suc-
ess was defined as exact deployment of the device according
he instructions for use using appropriate imaging modali-
ies. Technical success was defined as successful vascular
ccess, completion of the endovascular procedure, and
mmediate morphological success with 30% residual ste-
osis of the treated lesion by visual estimate. Procedural
uccess combines technical and device success with absence
f procedural complications. Data regarding the number of
rovisional stents implanted and the reason for stenting
persistent residual stenosis 50%, occlusive complication,
r dissection) was also analyzed. Follow-up duplex scan
ere performed by an independent operator.
Statistical analysis. Descriptive statistics (frequency and
percentage for categorical variables and number of observa-
tions, mean, standard deviation, median, minimum, and
maximum for continuous variables) were used to present
baseline and follow-up variables. Additionally, the Kaplan-
Meier estimate was used for presentation of primary patency
through 12 months. Inferential statistics were used as
follows: Rutherford classification and the categorical vari-
ables of QOL were compared using the Kruskal-Wallis test;
continuous variables (visual analogue scale, walking impair-
ment questionnaire, ABI, ACD, and PSVR) were com-
pared within group at different time points using the
Student t test. There was no correction for multiple com-
parisons. Primary patency was calculated from the hierar-
chical composite of TLR, binary restenosis (PSVR 2.4 by
duplex ultrasonography), and occlusion (PSVR  0).
The Euro QoL-5D levels were dichotomized into “no
problems” and “problems” for graphical presentation. The data
underwent inferential analysis using the Kruskal-Wallis test to
determine any statistical difference between the study visits.
An exploratory analysis was undertaken to identify predic-
tors of restenosis. The methodology used was a 2-step ap-
proach. First, possible predictors (occlusions, sex, reference
vessel diameter, lesion length, residual stenosis, calcification,
lesion location, deployment of stents, and diabetes) were
selected from the baseline variables and evaluated by analysis of
variance for continuous variables and chi-square test versus
restenosis for categorical variables. The second step was to
enter the variables in a binary logistic linear model (the
parameters were estimated via hybrid method (Fisher and
Newton-Raphson), chi-square and 95% confidence interval of
Wald and maximum likelihood). Variables with a p 0.05 are
considered significant predictors of restenosis.
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334Results
There were 105 patients representing 114 treated lesions
enrolled in the registry. The mean age of patients was 68 
9 years and 81% were men. There were high rates of
atherosclerotic risk factors among the enrolled patients and
42.9% had a history of coronary artery disease (Table 1). At
12-month follow-up, 92 of 105 (87.6%) enrolled patients
Figure 1. Patient Disposition
There is a high rate of patient follow-up at 3, 6, and 12 months post-PEB
procedure. DUS  duplex ultrasonography; PEB  paclitaxel-eluting
Table 1. Baseline Patient Demographics and Clinical Characteristics (N  105)
Age, yrs 68 9.0
Male 81.0 (85)
Hypertension 85.7 (90)
Hyperlipidemia 74.3 (78)
Diabetes mellitus 48.6 (51)
Insulin-dependent diabetes 21.9 (23)
Renal insufﬁciency* 1.9 (2)
Smoking, active and previous 62.8 (66)
Coronary artery disease 42.9 (45)
Carotid artery disease 14.3 (15)
ABI 0.56 0.15
Rutherford class, %
1 0.9
2 26.7
3 64.8
4 7.6
Values are mean  SD or % (n). *Renal insufficiency defined as glomerular filtration rate 30
ml/min as calculated by Cockcroft formula.
ABI ankle-brachial index.balloon(s).were evaluable and duplex ultrasonography was performed
on 77 (73.3%) patients (Fig. 1). Patients who did not return
for follow-up appointments were contacted by phone; no
adverse events were identified that could potentially relate to
the use of the PEB.
Lesions were predominantly located in the middle and
distal SFA (Table 2). Mean lesion length was 76.3  38.3
mm. Moderate (radiopacities on50% of the lesion area) to
severe (radiopacities on 50% of lesion area usually involv-
ing bilateral walls of the artery) calcification was present in
66.7% of lesions and 29.8% of the lesions were totally
occluded. There was no significant difference in lesion
length, reference vessel diameter, or calcification for the
totally occluded lesions compared with the nonoccluded
lesions.
Procedural and acute outcomes. All PEBs were successfully
eployed in all target vessels (device success  100%) and
he technical success rate was 89.6% (90.7% in totally
ccluded lesions) with 10.4% of lesions showing immediate
esidual stenosis 30%. Post-PEB dilation with a shorter
onventional uncoated balloon was performed in cases of
ersistent residual stenosis or dissections in 17.5% of the
ases. Ultimately, only 14 lesions (12.3%) were stented: 11 due
o persistent flow-limiting dissections and 3 for refractory
esidual stenosis 50% (Table 3). The need for stenting was
Table 2. Baseline Lesion Characteristics (N  114)
Lesion location
Proximal SFA 12.3 (14)
Middle SFA 48.2 (55)
Distal SFA 28.9 (33)
Popliteal artery 10.5 (12)
Lesion type
De novo 95.6 (109)
Restenotic 3.5 (4)
ISR 0.9 (1)
Calciﬁcation
None 33.3 (38)
Moderate 50.0 (57)
Severe 16.7 (19)
Lesion length 76.3 38.3
Reference vessel diameter 5.2 0.6
% diameter stenosis 92.5 8.2
Total occlusions 29.8 (34)
Inﬂow (iliac and common femoral)
Good 95.2 (100)
Impaired 4.8 (5)
Outﬂow (popliteal second and third segment, tibioperoneal
trunk, anterior tibial, posterior tibial, peroneal)
Good 37.1 (39)
Impaired 62.9 (66)
Values are % (n) or mean SD.ISR in-stent restenosis; SFA superficial femoral artery.
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335similar in occluded and nonoccluded lesions (14.7% vs. 11.2%,
p  0.541).
Clinical outcomes. The primary patency rate at 6 and 12
onths was 87.8% and 83.7%, respectively (Fig. 2). There
as no significant difference in primary patency between the
atients with lesions crossed subintimally and those with
rue lumen crossings (p  0.572). One patient death
ccurred before the 3-month follow-up due to cardiovascu-
ar causes with acute pulmonary edema and the second
atient death, between 6 and 12 months after procedure,
as of noncardiovascular causes (pulmonitis) and unrelated
o the device or procedure. The rate of TLR was 4.4% at 6
onths and 7.6% at 12 months (Table 4). One patient
nderwent a second TLR 410 days after the first occurrence.
ll TLR were clinically driven and confirmed angiographically
efore treatment; no reintervention was performed on positive
uplex findings in the absence of clinical symptoms. TLR
vents occurred at 4 different sites and were all caused by
estenosis; there were no total reocclusions. Overall, the 1-year
econdary patency rate was 90.2%. There were 3 (21.4%) reste-
osis events in the 14 patients who were stented and 12 (14.5%)
vents in the 83 patients not requiring a stent (p  NS). No
redictors of restenosis were identified.
The proportion of patients in Rutherford classes 2, 3, and
was significantly reduced by 3 months, and this clinical
enefit persisted out to 12 months (p  0.001) (Fig. 3).
imilar observations of significant, sustained improvement
ere made for change in ABI, PSVR, and ACD from
aseline to 12 months (p  0.0001 for each) (Fig. 4).
hanges in Rutherford class, ABI, PSVR, and ACD were
xamined for the totally occluded versus nonoccluded le-
ions, and there was no significant difference in any of these
utcome measures (p  0.506, 0.495, 1.000, and 0.434,
Table 3. Procedural and Acute Outcomes
Inﬂow re-established 100 (5)
Outﬂow re-established 100 (66)
Lesion crossing
True lumen 92.1 (105)
Subintimal 7.9 (9)
Pre-dilation 99.1 (113)
DEB inﬂation time, s 181 20.4
Number DEB per lesion 1.18 (135/114)
Device success 100 (135)
Technical success 89.6 (121)
Provisional stenting 12.3 (14)
Flow-limiting dissection 9.6 (11)
Persistent stenosis 50% 2.6 (3)
Residual % diameter stenosis 12.2 9.5
Range, min–max 0.0–40
Values are % (n) or mean SD. Patients, N 105; lesions, N 114.
DEB drug-eluting balloon(s).espectively, at 12 months).Walking capacity, based on the combined walking im-
airment questionnaire scores for walking distance, walking
peed, ability to climb stairs, and symptoms associated with
alking impairment, improved from a median score of 40.3
t baseline to 86.1 at 12 months.
Quality of life. Health-related QOL was also improved at 3,
6, and 12 months after the PEB procedure as reflected in
the decreased proportion of patients reporting problems on
the Euro QoL-5D questionnaire (Fig. 5). Significantly
fewer patients reported problems with mobility, usual activ-
ities, pain (p 0.001 for all 3), and anxiety/depression (p
0.002) at 3 months, and these benefits persisted throughout
the remaining 12-month study period. The overall visual
analogue scale health score at baseline was 66.8  12.3.
Significant improvement, reported at the 3-month follow-
up, was maintained through 12 months (81.3  12.7 at 3
onths, 77.6  12.4 at 12 months, p  0.001 for both).
iscussion
In the present registry, the safety and efficacy of a new PEB
catheter for the prevention of restenosis in atherosclerotic
femoropopliteal lesions was evaluated. The results of this
registry demonstrate that paclitaxel elution from a balloon is
safe for the prevention of restenosis in the superficial
femoral and popliteal arteries. Consistent benefit was ob-
served within an array of clinical and functional endpoints,
including walking capacity and QOL.
The concept of balloon-mediated elution is based on the
observation that sustained drug release is not a prerequisite
for long-lasting restenosis inhibition (27–30). Use of PEB
avoids or limits the usage of stents with associated risk for
stent fractures and combines local drug administration for
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Figure 2. Primary Patency; 12-Month Survival From TLR, Occlusion, and
>50% Restenosis
Kaplan-Meier curve for primary patency (PSVR 2.5). Error bars represent
SD. PSVR  peak systolic velocity ratio; TLR  target lesion revasculariza-
tion.
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336the prevention of restenosis with the mechanical effect of
balloon angioplasty. The efficacy of PEB in preventing
restenosis of the superficial femoral and popliteal arteries
has been reported in recent studies using the Paccocath
technology (MEDRAD Inc., Warrendale, Pennsylvania)
(21–23). These trials demonstrated significantly reduced
mean late loss and lower rates of TLR for PEB use
compared with standard balloon angioplasty (21,22).
After 12 months, the In.Pact Admiral PEB was associ-
ated with a high rate of primary (87.3%) and secondary
patency (90.2%) with a very low number of stents implanted
(12.3%), mainly to seal flow-limiting dissections. No failure
in reintervention was observed, showing the repeatability of
the intervention after PEB restenosis. Furthermore, there
was a similar rate of primary patency and limited stenting in
totally occluded lesions, which accounted for almost one-
third of treated lesions.
Most important, there was significant clinical benefit to
patients, as clearly demonstrated by the improvement in
ACD, ABI, and the reduction in Rutherford class. Within
3 months of the intervention, patients were able to walk
more than triple the distance they could previously walk,
and this functional benefit persisted to 12 months after the
PEB procedure. A corresponding shift in Rutherford class
occurred, and over 85% of patients remained in Rutherford
class 0 or 1 at 12 months. These clinical benefits were
similarly observed in patients with totally occluded lesions,
Table 4. Clinical Safety Outcomes at 3, 6, and 12 M
Endpoint
3 Month
(n  89
Death 1.1 (1)
Amputation 0 (0)
Target lesion revascularization 1.1 (1)
Values are % (n).
Figure 3. RC Change From Baseline
A signiﬁcant shift of patients to Rutherford classes (RC) 0 and 1 is observed
at 3, 6, and 12 months post-PEB procedure (p  0.001). PEB  paclitaxel-
eluting balloon(s).providing an important signal regarding the effectiveness of
the PEB in both stenotic and occluded SFA lesion.
This registry is the first study of PEB treatment for
atherosclerotic disease of the SFA to prospectively measure
6 Months
(n  90)
12 Months
(n  92)
1.1 (1) 2.2 (2)
0 (0) 0 (0)
4.4 (4) 7.6 (7)
A
B
C
Figure 4. Change in ABI, PSRV, and ACD From Baseline
The mean ankle-brachial index (ABI) (A), peak systolic velocity ratio (PSRV)
(B), and absolute claudication distance (ACD) (C) are signiﬁcantly improved
from baseline across all time points post-PEB procedure. Error bars repre-onths
s
)sent SD. PEB  paclitaxel-eluting balloon(s).
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337patients’ QOL at baseline and after the intervention. The
Euro QoL-5D questionnaire is a standardized measure of
health status applicable to a wide range of health conditions
and treatments. Across all 5 dimensions of health-related
QOL, the proportion of patients claiming a problem de-
clined and significant improvements were notable in the
areas of mobility, pain and discomfort, ability to pursue
usual activities, and anxiety and depression.
In the present registry, dual antiplatelet therapy was given
for 12 weeks (24 weeks if a stent was implanted). At the
time of the study design, no literature guided the selected
duration of dual antiplatelet therapy, thus it was empirically
chosen by the investigators to be longer than recommended
by the instructions for use as a precautionary measure at the
initial stage of adoption of this new technology. The
absence of thrombotic events following thienopyridine dis-
continuation in the current study suggests the safety of this
approach.
No predictors of restenosis were identified, which is not
surprising in this relatively small population with a low
number of events.
Study limitations. This multicenter registry entails the typ-
cal limitation of single-arm studies with the absence of a
ead-to-head comparator, and events were reported by each
tudy site without further adjudication. Interpretation of
unctional and QOL results are tempered by the lack of a
ontrol group.
onclusions
PTA of femoropopliteal arterial disease using PEB resulted
in a high primary patency rate that was sustained through 12
months with a low rate of stenting. Consistent improve-
ment in clinical endpoints, functional status, and associated
Figure 5. Change in Healthcare QOL Scores From Baseline
The percentage of patients reporting any problem across the 5 dimensions
of health-related quality of life (QOL) was reduced post-PEB procedure
(*p  0.001 for baseline vs. 3, 6, and 12 months; †p  0.002 for baseline
vs. 3, 6, and 12 months). PEB  paclitaxel-eluting balloon(s).QOL were observed. The low rate of TLR over 12 monthssuggests that the use of PEB offers durable safety and
effectiveness in this population. Larger, controlled trials are
indicated to further define the role of PEB for management
of patients with femoropopliteal arterial disease.
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